For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the emergence of Vyndamax and Tafamidis meglumine represents a significant advancement . These innovative therapies preserve the transthyretin protein, preventing its damaging build-up and alleviating the burden of the illness. Patients are now experi